JP2016514717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514717A5 JP2016514717A5 JP2016503655A JP2016503655A JP2016514717A5 JP 2016514717 A5 JP2016514717 A5 JP 2016514717A5 JP 2016503655 A JP2016503655 A JP 2016503655A JP 2016503655 A JP2016503655 A JP 2016503655A JP 2016514717 A5 JP2016514717 A5 JP 2016514717A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- indazol
- pyrimidin
- difluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 49
- 239000001257 hydrogen Substances 0.000 claims 46
- 229910052757 nitrogen Inorganic materials 0.000 claims 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000002431 hydrogen Chemical class 0.000 claims 22
- -1 cyano, hydroxy Chemical group 0.000 claims 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- 150000001204 N-oxides Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 150000004985 diamines Chemical class 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical compound NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 claims 2
- MMCMMTBSVJUFHW-UHFFFAOYSA-N 1-[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-5-morpholin-4-yl-6-(pyridin-4-ylamino)pyrimidin-4-yl]-3-ethylurea Chemical compound C1COCCN1C=1C(NC(=O)NCC)=NC(C=2C3=CC=CC=C3N(CC=3C(=CC(OCC)=CC=3F)F)N=2)=NC=1NC1=CC=NC=C1 MMCMMTBSVJUFHW-UHFFFAOYSA-N 0.000 claims 1
- WTFDZDWIIAAQKH-UHFFFAOYSA-N 1-[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-5-morpholin-4-yl-6-(pyrimidin-4-ylamino)pyrimidin-4-yl]-3-ethylurea Chemical compound C1COCCN1C=1C(NC(=O)NCC)=NC(C=2C3=CC=CC=C3N(CC=3C(=CC(OCC)=CC=3F)F)N=2)=NC=1NC1=CC=NC=N1 WTFDZDWIIAAQKH-UHFFFAOYSA-N 0.000 claims 1
- WMBMKGIKLXTQCC-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]-4-n-pyridin-4-ylpyrimidine-4,6-diamine Chemical compound N=1C(C=2C3=CC=CC=C3N(CC=3C(=CC=CC=3)F)N=2)=NC(N)=CC=1NC1=CC=NC=C1 WMBMKGIKLXTQCC-UHFFFAOYSA-N 0.000 claims 1
- HKNGDMQZJDIDIM-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4-(pyridin-4-ylamino)-8h-pyrimido[5,4-b][1,4]oxazin-7-one Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C3NC(=O)COC3=C(NC=3C=CN=CC=3)N=2)=N1 HKNGDMQZJDIDIM-UHFFFAOYSA-N 0.000 claims 1
- PRSKSAGOSNGOAW-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4-(pyrimidin-4-ylamino)-8h-pyrimido[5,4-b][1,4]oxazin-7-one Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C3NC(=O)COC3=C(NC=3N=CN=CC=3)N=2)=N1 PRSKSAGOSNGOAW-UHFFFAOYSA-N 0.000 claims 1
- ZYEPDTNWWYNQMR-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4-n,6-n-dipyridin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C=C(NC=3C=CN=CC=3)N=2)=N1 ZYEPDTNWWYNQMR-UHFFFAOYSA-N 0.000 claims 1
- QSMJNGHMLIMEKK-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4-n-pyridin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C=C(N)N=2)=N1 QSMJNGHMLIMEKK-UHFFFAOYSA-N 0.000 claims 1
- KWFBBBCFSQAVGP-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4-n-pyrimidin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3N=CN=CC=3)C=C(N)N=2)=N1 KWFBBBCFSQAVGP-UHFFFAOYSA-N 0.000 claims 1
- MRMZKDCVPVISJD-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-5-(2-methoxyethoxy)-4-n,6-n-dipyridin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(OCCOC)=C(NC=3C=CN=CC=3)N=2)=N1 MRMZKDCVPVISJD-UHFFFAOYSA-N 0.000 claims 1
- OJCLOFYBOCWJHZ-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-5-methoxy-4-n-pyridin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(OC)=C(N)N=2)=N1 OJCLOFYBOCWJHZ-UHFFFAOYSA-N 0.000 claims 1
- LVSXGIVVVNNEQC-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-5-methoxy-4-n-pyrimidin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3N=CN=CC=3)C(OC)=C(N)N=2)=N1 LVSXGIVVVNNEQC-UHFFFAOYSA-N 0.000 claims 1
- VWXCJRUFTDQCSU-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-5-morpholin-4-yl-4-n-pyridin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(N3CCOCC3)=C(N)N=2)=N1 VWXCJRUFTDQCSU-UHFFFAOYSA-N 0.000 claims 1
- PKWCXBWUKXWURO-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-5-morpholin-4-yl-4-n-pyrimidin-4-ylpyrimidine-4,6-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3N=CN=CC=3)C(N3CCOCC3)=C(N)N=2)=N1 PKWCXBWUKXWURO-UHFFFAOYSA-N 0.000 claims 1
- DGMHYDKXRJMTSU-UHFFFAOYSA-N 2-[4-amino-2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl]oxyethanol Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(OCCO)=C(N)N=2)=N1 DGMHYDKXRJMTSU-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- UXJCOUNVVVHUKU-UHFFFAOYSA-N 6-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-2-n,4-n-dipyridin-4-yl-1,3,5-triazine-2,4-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)N=C(NC=3C=CN=CC=3)N=2)=N1 UXJCOUNVVVHUKU-UHFFFAOYSA-N 0.000 claims 1
- QOQTWUMAGLNSSE-UHFFFAOYSA-N 6-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-2-n-pyridin-4-yl-1,3,5-triazine-2,4-diamine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)N=C(N)N=2)=N1 QOQTWUMAGLNSSE-UHFFFAOYSA-N 0.000 claims 1
- WLAGGCHGKHPGBX-UHFFFAOYSA-N C(C)OC1=CC(=C(CN2N=C(C3=CC=CC=C23)C2=NC(=C(C(=N2)NC2=CC=NC=C2)OC)NC2=CC=NC=C2)C(=C1)F)F Chemical compound C(C)OC1=CC(=C(CN2N=C(C3=CC=CC=C23)C2=NC(=C(C(=N2)NC2=CC=NC=C2)OC)NC2=CC=NC=C2)C(=C1)F)F WLAGGCHGKHPGBX-UHFFFAOYSA-N 0.000 claims 1
- ZOVSEBNXJMPRFC-UHFFFAOYSA-N FC1=C(CN2N=C(C3=CC=CC=C23)C2=NC(=CC(=N2)NC2=CC=NC=C2)NC2=CC=NC=C2)C=CC=C1 Chemical compound FC1=C(CN2N=C(C3=CC=CC=C23)C2=NC(=CC(=N2)NC2=CC=NC=C2)NC2=CC=NC=C2)C=CC=C1 ZOVSEBNXJMPRFC-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- UIRZNORYCBEJBT-UHFFFAOYSA-N n-[2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-4-yl]-2-methoxyacetamide Chemical compound N=1C(C=2C3=CC=CC=C3N(CC=3C(=CC=CC=3)F)N=2)=NC(NC(=O)COC)=CC=1NC1=CC=NC=C1 UIRZNORYCBEJBT-UHFFFAOYSA-N 0.000 claims 1
- AMNFLSCVDAEWNM-UHFFFAOYSA-N n-[2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-4-yl]acetamide Chemical compound N=1C(C=2C3=CC=CC=C3N(CC=3C(=CC=CC=3)F)N=2)=NC(NC(=O)C)=CC=1NC1=CC=NC=C1 AMNFLSCVDAEWNM-UHFFFAOYSA-N 0.000 claims 1
- LQKLSDYWEJADER-UHFFFAOYSA-N n-[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4,6-bis(pyridin-4-ylamino)pyrimidin-5-yl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(NS(=O)(=O)C(F)(F)F)=C(NC=3C=CN=CC=3)N=2)=N1 LQKLSDYWEJADER-UHFFFAOYSA-N 0.000 claims 1
- NMENTUZNGFMPHD-UHFFFAOYSA-N n-[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4,6-bis(pyridin-4-ylamino)pyrimidin-5-yl]-2-methoxyacetamide Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(NC(=O)COC)=C(NC=3C=CN=CC=3)N=2)=N1 NMENTUZNGFMPHD-UHFFFAOYSA-N 0.000 claims 1
- IGNRQACPPPZQHP-UHFFFAOYSA-N n-[2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-4,6-bis(pyrimidin-4-ylamino)pyrimidin-5-yl]-2-methoxyacetamide Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3N=CN=CC=3)C(NC(=O)COC)=C(NC=3N=CN=CC=3)N=2)=N1 IGNRQACPPPZQHP-UHFFFAOYSA-N 0.000 claims 1
- KOBDLRLAAOEDJE-UHFFFAOYSA-N n-[4-amino-2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl]-1,1,1-trifluoromethanesulfonamide Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(NS(=O)(=O)C(F)(F)F)=C(N)N=2)=N1 KOBDLRLAAOEDJE-UHFFFAOYSA-N 0.000 claims 1
- NCCPYYXVJNZUII-UHFFFAOYSA-N n-[4-amino-2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl]-2-methoxyacetamide Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(NC(=O)COC)=C(N)N=2)=N1 NCCPYYXVJNZUII-UHFFFAOYSA-N 0.000 claims 1
- JWZNTYCVYQIPEJ-UHFFFAOYSA-N n-[4-amino-2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-6-(pyridin-4-ylamino)pyrimidin-5-yl]ethanesulfonamide Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3C=CN=CC=3)C(NS(=O)(=O)CC)=C(N)N=2)=N1 JWZNTYCVYQIPEJ-UHFFFAOYSA-N 0.000 claims 1
- MIUCUJQELFUMPE-UHFFFAOYSA-N n-[4-amino-2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]indazol-3-yl]-6-(pyrimidin-4-ylamino)pyrimidin-5-yl]-2-methoxyacetamide Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C2=CC=CC=C2C(C=2N=C(NC=3N=CN=CC=3)C(NC(=O)COC)=C(N)N=2)=N1 MIUCUJQELFUMPE-UHFFFAOYSA-N 0.000 claims 1
- TVGVZZLCEMHNAR-UHFFFAOYSA-N n-[6-(dipyridin-4-ylamino)-2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]pyrimidin-4-yl]-2-methoxyacetamide Chemical compound N=1C(NC(=O)COC)=CC(N(C=2C=CN=CC=2)C=2C=CN=CC=2)=NC=1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1F TVGVZZLCEMHNAR-UHFFFAOYSA-N 0.000 claims 1
- UFRZQPMZYXWJOU-UHFFFAOYSA-N n-[6-(dipyridin-4-ylamino)-2-[1-[(2-fluorophenyl)methyl]indazol-3-yl]pyrimidin-4-yl]acetamide Chemical compound N=1C(NC(=O)C)=CC(N(C=2C=CN=CC=2)C=2C=CN=CC=2)=NC=1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1F UFRZQPMZYXWJOU-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160350.8 | 2013-03-21 | ||
| EP13160350 | 2013-03-21 | ||
| PCT/EP2014/055540 WO2014147144A1 (en) | 2013-03-21 | 2014-03-19 | Diaminoheteroaryl substituted indazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514717A JP2016514717A (ja) | 2016-05-23 |
| JP2016514717A5 true JP2016514717A5 (enExample) | 2017-04-20 |
Family
ID=47900948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503655A Pending JP2016514717A (ja) | 2013-03-21 | 2014-03-19 | ジアミノヘテロアリール置換インダゾール |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160052912A1 (enExample) |
| EP (1) | EP2976334A1 (enExample) |
| JP (1) | JP2016514717A (enExample) |
| CN (1) | CN105051030A (enExample) |
| AR (1) | AR095708A1 (enExample) |
| CA (1) | CA2907730A1 (enExample) |
| HK (1) | HK1217324A1 (enExample) |
| TW (1) | TW201514167A (enExample) |
| UY (1) | UY35499A (enExample) |
| WO (1) | WO2014147144A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| WO2013092512A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| WO2014147203A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CA2907594A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| US9765058B2 (en) | 2013-06-21 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| HK1223098A1 (zh) | 2013-06-21 | 2017-07-21 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吡唑 |
| US9682974B2 (en) | 2013-10-30 | 2017-06-20 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| UY36175A (es) | 2014-06-17 | 2016-01-29 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas |
| AU2015316796A1 (en) | 2014-09-19 | 2017-03-30 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as Bub1 inhibitors |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| JP7090639B2 (ja) | 2017-04-11 | 2022-06-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | フッ素置換されたインダゾール化合物及びその使用 |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4686299A (en) * | 1998-06-16 | 2000-01-05 | Sugen, Inc. | Nek-related and bub1-related protein kinases |
| US7378532B2 (en) * | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| TW201038567A (en) * | 2009-03-27 | 2010-11-01 | Pathway Therapeutics Ltd | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| WO2013092512A1 (en) * | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| HK1207861A1 (en) * | 2012-05-11 | 2016-02-12 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| WO2014147203A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CA2907594A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
-
2014
- 2014-03-19 US US14/778,604 patent/US20160052912A1/en not_active Abandoned
- 2014-03-19 JP JP2016503655A patent/JP2016514717A/ja active Pending
- 2014-03-19 HK HK16105232.9A patent/HK1217324A1/zh unknown
- 2014-03-19 CN CN201480017090.3A patent/CN105051030A/zh active Pending
- 2014-03-19 WO PCT/EP2014/055540 patent/WO2014147144A1/en not_active Ceased
- 2014-03-19 EP EP14710931.8A patent/EP2976334A1/en not_active Withdrawn
- 2014-03-19 CA CA2907730A patent/CA2907730A1/en not_active Abandoned
- 2014-03-21 TW TW103110771A patent/TW201514167A/zh unknown
- 2014-03-21 AR ARP140101321A patent/AR095708A1/es unknown
- 2014-03-24 UY UY0001035499A patent/UY35499A/es not_active Application Discontinuation
-
2017
- 2017-03-28 US US15/471,885 patent/US20170283396A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514717A5 (enExample) | ||
| JP2016522231A5 (enExample) | ||
| JP6487925B2 (ja) | セリン／トレオニンキナーゼ阻害剤 | |
| JP2016522232A5 (enExample) | ||
| JP6529492B2 (ja) | 癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物 | |
| JP2016514718A5 (enExample) | ||
| CA2997039C (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| JP2014531465A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| KR20130130030A (ko) | Vps34 억제제로서의 비-헤테로아릴 화합물 | |
| US20240300927A1 (en) | Amides as cbl-b inhibitors | |
| CA2531619A1 (en) | Biaryl piperazinyl-pyridine analogues | |
| JP2016514719A5 (enExample) | ||
| JP2022551422A (ja) | ピリドン化合物およびタンパク質キナーゼの調節における使用の方法 | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| MX2014014112A (es) | Nuevos compuestos. | |
| KR20150140688A (ko) | 치환된 인돌-5-올 유도체와 그들의 치료적 용도 | |
| JP2009537606A5 (enExample) | ||
| JP2021510729A (ja) | 受容体チロシンキナーゼのｔｙｒｏ３、ａｘｌおよびｍｅｒｔｋ（ｔａｍ）ファミリー阻害剤としてのヘテロ環化合物 | |
| JP2016505059A5 (enExample) | ||
| CN117157284A (zh) | Ctla-4小分子降解剂及其应用 | |
| MX2016000386A (es) | Proceso para la preparacion de un intermediario de pirimidina. | |
| TWI624461B (zh) | 喹唑啉化合物，其製備方法及用途 | |
| HK1223923B (zh) | 用於治療癌症的作為idh2突變體抑制劑的2，4-或4，6-二氨基嘧啶化合物 | |
| HK1223877B (zh) | 絲氨酸/蘇氨酸激酶抑制劑 |